Sun Pharma buys Organon for $11.75bn, doubles revenue

The headline deal

Sun Pharmaceutical Industries has agreed to acquire US-listed Organon & Co. in an all-cash transaction valued at an enterprise value of $11.75 billion. The acquisition is positioned as the biggest-ever deal by an Indian pharmaceutical company, and it materially increases Sun Pharma’s global scale. Under the definitive agreement, Sun Pharma will buy all outstanding shares of Organon for $14.00 per share in cash. The transaction has been approved by the boards of both companies. Closing is expected in early 2027, subject to Organon shareholder and regulatory approvals.

What Sun Pharma is buying

Organon was spun off from Merck in 2021 and focuses on women’s health, biosimilars, and established medicines. The company has a portfolio of more than 70 products across women’s health and general medicines, including biosimilars. These products are commercialised across 140 countries, giving Sun Pharma an immediately broader international commercial platform. Sun Pharma has said the combination will strengthen its presence in women’s health, established brands, and biosimilars while expanding reach in advanced markets. The deal also fits Sun Pharma’s stated aim of building new growth engines beyond traditional generics.

Financial scale: revenue and EBITDA step-up

Sun Pharma has framed the acquisition as a step-change in size. Post-integration, the combined Sun-Organon entity is expected to generate $12.4 billion in annual revenue, compared with Sun Pharma’s standalone $1.2 billion revenue in FY25. Combined EBITDA is expected to rise to about $1.7 billion after integration. For context on Organon’s recent base, Organon reported $1.2 billion in revenue and adjusted EBITDA of $1.9 billion for the year ended December 31, 2025.

Deal terms and the premium

The agreement sets a cash purchase price of $14.00 per share for Organon. Reuters reported the price represents a premium of more than 24% to Organon’s last close on Friday before the announcement. Separately, reporting in the provided context also noted Organon shares rose about 30% in premarket trading following the news. Sun Pharma’s executive chairman Dilip Shanghvi said Organon’s portfolio, capabilities and global reach are highly complementary to Sun Pharma’s own, and that combining the organisations can create a stronger and more diversified platform.

Funding plan: cash plus committed financing

Sun Pharma said it plans to finance the transaction through a mix of $1.0 billion to $1.5 billion of cash on its balance sheet and $1.25 billion to $1.75 billion of committed bank financing. The structure keeps the deal fully cash-funded while relying heavily on debt financing. Organon’s balance sheet is also a key part of the enterprise value math. Organon had debt of $1.6 billion and a cash balance of $1.574 billion as of the end of 2025.

Integration goals and synergy targets

Sun Pharma expects potential synergies of over $1.35 billion within two to four years of integration. The company has linked these synergies to cost efficiencies, supply-chain optimisation, and applying Sun Pharma’s branded-generics execution approach to Organon’s established brands. The transaction is expected to be effected by a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the merger. Organon also recently closed a divestiture of a product and received an upfront payment of $1.44 billion, with net proceeds expected to contribute to its March 31, 2026 cash balance.

What the combined footprint looks like

Sun Pharma said that, once completed, the combined company will have a presence across all major pharmaceutical markets. It also expects 18 countries to each generate more than $1.1 billion in revenue after the combination. The combined global commercial workforce is expected to be about 24,000 people. Management has positioned this larger platform as supportive of deeper patient access across therapies and regions, and as a stronger base for global licensing discussions.

Key numbers at a glance

Timeline and approvals

Why this matters for Indian pharma and investors

In size alone, the acquisition stands out for Indian outbound healthcare deal-making. The expected move from $1.2 billion to $12.4 billion in annual revenue reframes Sun Pharma’s global scale, and the company has explicitly tied the transaction to expanding beyond traditional generics. The focus areas in the announcement, women’s health, biosimilars, and established medicines, signal where Sun Pharma expects durable cash flows and broader commercial reach. Sun Pharma also said the enlarged platform can help it become a stronger partner for global licensing deals, supported by a wider country footprint and a larger commercial organisation.

What to watch next

The next formal milestones are the shareholder vote at Organon and regulatory clearances, both required before closing. Investors will also track the final financing package within the stated ranges, and progress against the synergy target of over $1.35 billion within two to four years. Sun Pharma has guided to completion in early 2027, which sets the timeline for when the combined revenue and EBITDA profile can begin to be assessed against the company’s stated expectations.